Ładuje się......
Exposure‐response analysis after subcutaneous administration of RBP‐7000, a once‐a‐month long‐acting Atrigel formulation of risperidone
AIMS: A new, long‐acting, subcutaneous (SC) formulation of risperidone (RBP‐7000) has been developed for the treatment of schizophrenia to address issues of non‐adherence associated with oral risperidone treatment. The objective of this work was to establish an exposure‐response relationship between...
Zapisane w:
| Wydane w: | Br J Clin Pharmacol |
|---|---|
| Główni autorzy: | , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
John Wiley and Sons Inc.
2017
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5465337/ https://ncbi.nlm.nih.gov/pubmed/28133766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13246 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|